Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock?

Novo Nordisk’s oral Wegovy recorded roughly 18,000 prescriptions in its second week on the market versus about 8,000 prescriptions for Eli Lilly’s injectable Zepbound in its second week, a gap highlighted by Evercore ISI analyst Umer Raffat (who noted the 18,000 figure excludes online prescriptions). Novo shares pulled back after early gains on the report; the pronounced early demand for the oral Wegovy suggests stronger launch traction and potential market-share implications in the GLP-1 weight-loss market that could affect near-term valuations for NVO and competitive dynamics for LLY.

Analysis

Market structure: The 18,000 second‑week oral Wegovy scripts vs Lilly’s 8,000 injectable scripts is a clear early signal of product preference and distribution advantage for NVO; if weekly scripts stay 2x higher through the next 4–8 weeks, model a 5–15% revenue upside to consensus for NVO over the next 12 months as oral convenience expands the addressable market. Direct winners: NVO, retail pharmacies, specialty distributors and API suppliers; losers: LLY’s weight‑loss injectable franchise and smaller GLP‑1 injectors facing pricing pressure and share loss. Cross‑asset: stronger NVO adoption is mildly pro‑risk (equities up, IG spreads tighten 5–10bp on healthcare outperformance), with limited FX moves but potential commodity/APIs demand tightening driving upstream input price pressure for key excipients.

Risk assessment: Tail risks include regulator safety flags or label changes (probability ~5–10% in 12 months), aggressive payer rebate/step therapy pushes (could shave 10–30% off realized price), and manufacturing bottlenecks causing 1–3 month supply lags. Time horizons: expect headline volatility in days, prescription share confirmation over 2–8 weeks, and material P&L effects in quarters (2–4). Hidden dependencies: PBM formulary decisions, online Rx counts (excluded from the 18k) and API capacity; catalysts — weekly script releases, earnings guidance, and payer negotiations in the next 30–90 days.

Trade implications: Tactical: establish a 2–3% long position in NVO within 3 trading days, target +12–20% in 3–6 months, stop‑loss 8% on entry. Hedged/relative: pair trade long NVO (2%) / short LLY (1–1.5%) or buy LLY 3‑month 10% OTM puts sized to 1% portfolio to limit downside. Options: prefer 4–6 month NVO call spreads (buy ATM, sell 15–20% OTM) to capture upside while capping premium; trim if NVO rallies >7% on a single day.

Contrarian angles: Consensus prizes raw script counts but underrates payer resistance and durability of weight‑loss response — if weekly Wegovy script growth decelerates to <5% week‑over‑week for three consecutive weeks, downside reprice risk is large. LLY’s broader diabetes franchise and pipeline (Mounjaro) mean its long‑term earnings risk is asymmetric; shorting LLY outright is riskier than a small put hedge. Historical parallel: initial Ozempic headline spikes were followed by competitive pricing and step‑therapy battles that trimmed margins by mid‑cycle (5–10%), so size positions accordingly.

Key Decisions for Investors

• Establish a 2–3% long position in NVO within the next 3 trading days; target +12–20% upside over 3–6 months, set an initial stop‑loss at 8% below entry and trim 50% of the position on a >15% move higher.
• Implement a pair trade: long NVO (2% portfolio) and short LLY (1–1.5%); if unwilling to short equity, buy LLY 3‑month 10% OTM puts sized to 1% portfolio as downside protection; unwind after 3 months or if relative outperformance exceeds 15%.
• Use options to express asymmetric upside: buy 4–6 month NVO call spread (buy ATM, sell 15–20% OTM) sized to 0.75–1% portfolio risk to limit premium outlay; sell 1/3 position if weekly Wegovy scripts fall below 10k for any week.
• Reduce exposure by 1–2% to smaller obesity/GLP‑1‑dependent mid/small caps and reallocate to large‑cap pharma suppliers and NVO; reassess after 4 weekly prescription datapoints or any major payer formulary decision within 30–60 days.